(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Far-right German youth group delegates seek deportations, remigration - 2One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- 3Find Your Ideal Tea: Six Particular Assortments
- 4Lebanon says Israeli strike killed 13 people near Palestinian refugee camp
- 5'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
- Trial of pro-Palestine activist begins
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
- San Francisco mayor says city in talks to bring pandas back to zoo ahead of trip to Asia
- The Best Competitors of the 21st Hundred years
- Farmers call for French blockades over cow disease cull
- Lilly, Novo lock horns in India's obesity drug race
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- Report: Thailand strikes deal with Iran for safe passage of Hormuz
- How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
